AHA 22 - Principal investigator of the PRECISE Trial (NCT03702244), Dr Pamela Douglas (Duke University School of Medicine, US) joins Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) to discuss the trial design and the new data presented at the Scientific Sessions.

The rationale of the PRECISE trial was to evaluate if a precision approach of coronary-CTA-led diagnostic pathways tailored to patient risk improved clinical outcomes in patients with CAD as compared to usual care. Patients in the "precision evaluation strategy" arm with elevated risk were assessed based on pretest clinical characteristics using the PROMISE risk tool. 

The study demonstrated the net clinical effectiveness of the precision strategy with a 65% reduction of the composite of death, non-fatal MI or catheterization without obstructive CAD, compared to usual testing at 1 year.

Access our full AHA 22 Scientific Coverage here.  

Recorded remotely from Hamilton and Durham, 2022.

Editor: Mirjam Boros, Jordan Rance
Video Specialists: Dan Brent, Oliver Miles